Screener / SEC EDGAR /CIK 0001158895 /10-K filed Feb 26, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

Lemaitre Vascular Inc LMAT

Compare with peers Embed
Earnings releases

Latest results release: Nov 4, 2026

8-K item 2.02, exhibit 99

What LMAT's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

What the company says its adjusted numbers leave out:

Additionally, the Company has provided percentages for Q3 2026 operating income, gross margin, operating expense and EPS, as well as operating income and EPS guidance, adjusted to exclude the effects of the employee retention tax credit received in 2025. release Nov 4, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 4, 2026 · EX-99.1

Exhibit 99.1 LeMaitre Q3 2026 Financial Results BURLINGTON, MA, November 4, 2026

Open on SEC

Exhibit 99.1 LeMaitre Q3 2026 Financial Results BURLINGTON, MA, November 4, 2026 – LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance. Q3 2026:

Grafts (+20%) and shunts (+14%) drove Q3 growth. Artegraft sales increased 18%. EMEA sales increased by 18%, Americas 9%, and APAC 5%. 12% organic growth was comprised of 7% price and 5% units. Gross margin of 71.7% was up 90 bps (vs. adjusted) due to higher ASPs and operational efficiencies. Operating expenses increased 18% (vs. adjusted) due to Q3 2025 belt-tightening. Headcount of 678 increased 7% versus 9/30/2025 while rep count increased 13% to 171. In October, the company acquired certain vascular assets from B. Braun for $19.2mm. These polyester and silver-coated grafts, valve cutters and vein strippers recorded sales of $9.4mm in 2025, all outside of North America. Sales will transition into LeMaitre’s channel over the next 18-24months as B. Braun’s customer contracts conclude or transfer to LeMaitre. During this transition, LeMaitre will receive a portion of the profits on B. Braun-originated sales. Chairman/CEO George LeMaitre said, “We expect 2026 to be another year of healthy sales (+11%) and EPS growth (+18%). Biologics continue to drive sales due to Artegraft’s international launch and the continued growth of RestoreFlow Allografts. The acquired B. Braun products will strengthen our core vascular portfolio while leveraging our expanding 31-countrysales force.” Business Outlook

The top- and bottom-line impacts of the newly acquired B. Braun * products are reflected in this Business Outlook. LeMaitre anticipates recording ~$150,000 of Q4 2026 B. Braun product sales and break-even operating income impact.

2025 results include a Q3 non-recurring benefit from the Employee ** Retention Tax Credit. Non-GAAP adjusted figures exclude this benefit. A reconciliation of GAAP to non-GAAP measures is included.

Quarterly Dividend On October 27, 2026, the Company’s Board of Directors approved a quarterly dividend of $0.25/share of common stock. The dividend will be paid on December 3, 2026, to stockholders of record on November 19, 2026. Share Repurchase Program On February 19, 2026, the Company’s Board of Directors authorized the repurchase of up to $100.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 18, 2027, unless extended by the Board.

Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company’s website at . Access to the live call is available by registering online . All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at . For individuals unable to join the live conference call, a replay will be available on the Company’s website.

A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.

LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.

LeMaitre management believes that in order to better understand the Company’s short- and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, GAAP financial performance measures. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.

In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events. The Company refers to the calculation of non-GAAP sales growth percentages as “organic” or “adjusted.” The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, factory closures, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. Additionally, the Company has provided percentages for Q3 2026 operating income, gross margin, operating expense and EPS, as well as operating income and EPS guidance, adjusted to exclude the effects of the employee retention tax credit received in 2025. Management believes that viewing growth in these measures excluding those effects provides an alternative and meaningful view of the Company’s profitability.

Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures set forth in the tables captioned “Reconciliation of GAAP to Non-GAAP Financial Measures” below.

The Company’s current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, our ability to maintain historic levels of profit growth; our ability to increase the selling prices of our products; the status of our regulatory approvals, compliance with regulatory requirements, and the potential for adverse regulatory findings or enforcement actions arising from inspections, audits, or other regulatory reviews, affecting our ability to market and sell our products domestically and internationally; our ability to source, acquire, and integrate acquisitions; our dependence on sole- or limited-source suppliers; competition from other medical device companies and alternative medical technologies; our ability to engage sales call points other than vascular surgeons; disruptions to our information technology systems or breaches of our information security systems; our implementation of our new enterprise resource planning system; our ability to procure, process, and preserve human tissue and comply with relevant regulatory requirements; the impact of a disruption in our manufacturing facilities; our ability to navigate the risks inherent in operating internationally; our ability to transition to direct sales models in certain international territories; the occurrence of

litigation relating to product liability, employment matters, intellectual property, contract disputes, and other matters; the occurrence of product defects or recalls; our ability to service and repurchase our debt; the dilutive effect of a conversion of our debt; our ability to navigate executive officer transitions and retain key personnel; our ability to protect our intellectual property; volatility in the price of our common stock; and other risks and uncertainties included under the heading “Risk Factors” in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) CONDENSED CONSOLIDATED BALANCE SHEETS (amounts in thousands)

September 30, December 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── -unaudited Assets Current assets: Cash and cash $ 27,493 $ 28,244 equivalents Short-term marketable 362,228 330,876 securities Accounts receivable, 35,876 33,610 net Inventory and other deferred 71,272 70,422 costs Prepaid expenses and 8,642 5,080 other current assets Total current 505,511 468,232 assets Property and 30,465 26,997 equipment, net Right-of-use 18,503 15,762 leased assets Goodwill 65,945 65,945 Other intangibles, 29,295 33,089 net Deferred tax 746 759 assets Other assets 5,567 4,906 Total assets $ 656,032 $ 615,690 Liabilities and stockholders’ equity Current liabilities: Accounts $ 4,159 $ 3,646 payable Accrued 26,686 29,411 expenses Acquisition-r… 583 322 obligations Lease liabilities - 3,192 2,944 short-term Total current 34,620 36,323 liabilities Convertible senior notes, 169,317 168,645 net Lease liabilities - 16,342 14,003 long-term Deferred tax 2,167 1,735 liabilities Other long-term 1,455 1,468 liabilities Total 223,901 222,174 liabilities Stockholders’ equity Common stock 245 244 Additional paid-in 238,938 228,407 capital Retained 215,324 184,715 earnings Accumulated other (4,460 ) (2,411 ) comprehensive loss Treasury stock (17,916 ) (17,439 ) Total stockholders’ 432,131 393,516 equity Total liabilities and $ 656,032 $ 615,690 stockholders’ equity

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (amounts in thousands, except per share amounts) (unaudited)

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (amounts in thousands) (unaudited)

For the nine September 30, September 30, months ended 2026 2025 ────────────────────────────────────────────────────────────────────────────── Operating activities Net income $ 47,753 $ 42,152 Adjustments to reconcile net income to net cash provided by operating activities Depreciation and 8,170 7,813 amortization Stock-based 6,056 5,730 compensation Amortization of issuance costs on 672 653 convertible notes Non-cash investment (253 ) — income Provision for inventory 2,548 1,893 write-downs Provision for 675 455 credit losses Foreign currency transaction 316 (79 ) effect on income Changes in operating assets and liabilities: Accounts (3,347 ) (1,403 ) receivables Inventory and other deferred (3,584 ) (6,805 ) costs Prepaid expenses and (4,244 ) 1,639 other assets Accounts payable and (636 ) 5,327 other liabilities Accrued (1,078 ) 719 interest Net cash provided by 53,048 58,094 operating activities Investing activities Purchases of short-term (390,987 ) (43,015 ) marketable securities Purchases of property and (7,429 ) (5,006 ) equipment Payments related to acquisitions, (194 ) (95 ) net of cash acquired Proceeds from short-term 358,201 — marketable securities Net cash used in investing (40,409 ) (48,116 ) activities Financing activities Proceeds from stock option 4,473 4,657 exercises Deferred payments for (95 ) (1,433 ) acquisitions Payment of withholding taxes in connection (477 ) (605 ) with net settlement of equity awards Common stock cash dividend (17,144 ) (13,572 ) paid Net cash used in financing (13,243 ) (10,953 ) activities Effect of exchange rate changes on (147 ) 859 cash and cash equivalents Net (decrease) increase in (751 ) (116 ) cash and cash equivalents Cash and cash equivalents at 28,244 25,610 beginning of period Cash and cash equivalents at $ 27,493 $ 25,494 end of period

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) SELECTED NET SALES INFORMATION (amounts in thousands) (unaudited)

LEMAITRE VASCULAR, INC (NASDAQ: LMAT) RECONCILIATION OF GAAP TO NON- GAAPFINANCIAL MEASURES (amounts in thousands) (unaudited)

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) RECONCILIATION OF GAAP TO NON- GAAPFINANCIAL MEASURES (amounts in thousands) (unaudited)

Reconciliation between GAAP and Non-GAAP sales growth: For the three months ended September 30, 2026 ────────────────────────────────────────────────────────────────────────────── Net sales as reported $ 67,970 Impact of currency exchange rate 439 fluctuations Adjusted net sales $ 68,409 For the three months ended September 30, 2025 Net sales as reported $ 61,046 Adjusted net sales $ 61,046 Adjusted net sales increase for the $ 7,363 12 % three months ended September 30, 2026 Reconciliation between GAAP and Non-GAAP gross margin growth: For the three months ended September 30, 2026 Gross margin as reported 71.7 % Adjusted gross margin 71.7 % For the three months ended September 30, 2025 Gross margin as reported 75.3 % Employee Retention Tax Credit -4.5 % impact Adjusted gross margin 70.8 % Adjusted gross margin increase for the 0.9 % three months ended September 30, 2026 Reconciliation between GAAP and Non-GAAP operating expense growth: For the three months ended September 30, 2026 Operating expense as reported $ 31,010 Adjusted operating expense $ 31,010 For the three months ended September 30, 2025 Operating expense as reported $ 25,643 Employee Retention Tax Credit 667 impact Adjusted operating expense $ 26,310 Adjusted operating expense increase for the three months ended September $ 4,700 18 % 30, 2026 Reconciliation between GAAP and Non-GAAP operating income growth: For the three months ended September 30, 2026 Operating income as reported $ 17,695 Adjusted operating income $ 17,695 For the three months ended September 30, 2025 Operating income as reported $ 20,312 Employee Retention Tax Credit (3,380 ) impact Adjusted operating income $ 16,932 Adjusted operating income increase for the three months ended September $ 763 5 % 30, 2026 Reconciliation between GAAP and Non-GAAP earnings per share growth: For the three months ended September 30, 2026 Earnings per share as reported $ 0.65 Adjusted earnings per share $ 0.65 For the three months ended September 30, 2025 Earnings per share as reported $ 0.75 Employee Retention Tax Credit (0.13 ) impact Adjusted earnings per share $ 0.62 Adjusted earnings per share increase for the three months ended September $ 0.03 5 % 30, 2026

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) RECONCILIATION OF GAAP TO NON- GAAPFINANCIAL MEASURES (amounts in thousands) (unaudited)

Reconciliation between GAAP and Non-GAAP projected sales growth: For the three months ending December 31, 2026 ────────────────────────────────────────────────────────────────────────────── Net sales per guidance (midpoint) $ 70,900 Impact of currency exchange rate 507 fluctuations Adjusted projected net sales $ 71,407 For the three months ended December 31, 2025 Net sales as reported $ 64,453 Adjusted net sales $ 64,453 Adjusted projected net sales increase for the three months ending December $ 6,954 11 % 31, 2026 Reconciliation between GAAP and Non-GAAP projected sales growth: For the year ending December 31, 2026 Net sales per guidance (midpoint) $ 275,800 Impact of currency exchange rate (1,433 ) fluctuations Adjusted projected net sales $ 274,367 For the year ended December 31, 2025 Net sales as reported $ 249,602 Net impact of divestitures excluding (1,839 ) currency Adjusted net sales $ 247,763 Adjusted projected net sales increase $ 26,604 11 % for the year ending December 31, 2026 Reconciliation between GAAP and Non-GAAP projected operating income growth: For the year ending December 31, 2026 Operating income per guidance $ 75,400 (midpoint) Projected operating income $ 75,400 For the year ended December 31, 2025 Operating income as reported $ 67,912 Impact of employee retention credit (3,380 ) Adjusted operating income $ 64,532 Adjusted projected operating income increase for the year ending $ 10,868 17 % December 31, 2026 Reconciliation between GAAP and Non-GAAP earnings per share growth: For the year ending December 31, 2026 Earnings per share per guidance $ 2.80 (midpoint) Projected earnings per share $ 2.80 For the year ended December 31, 2025 Earnings per share as reported $ 2.52 Impact of employee retention credit (0.14 ) Adjusted earnings per share $ 2.38 Adjusted projected earnings per share increase for the year ending $ 0.42 18 % December 31, 2026

Full text with the tables
Exhibit 99.1 LeMaitre Q3 2026 Financial Results BURLINGTON, MA, November 4, 2026
– LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices,
implants, and services, today reported Q3 2026 results, announced a quarterly
dividend of $0.25/share, and provided guidance. Q3 2026:
                                                       
  •    Sales $68.0mm, +11% (+12% organic) vs. Q3 2025  
                                                       
                                                           
  •    Gross margin 71.7% (-360bps, +90 bps vs. adjusted)  
                                                           
                                                       
  •    Op. expenses $31.0mm (+21%, +18% vs. adjusted)  
                                                       
                                                    
  •    Op. income $17.7mm (-13%, +5% vs. adjusted)  
                                                    
                       
  •    Op. margin 26%  
                       
                                           
  •    EPS $0.65 (-14%, +5% vs. adjusted)  
                                           
                                                            
  •    Cash up $13.5mm sequentially to $390mm at 9/30/2026  
                                                            
Grafts (+20%) and shunts (+14%) drove Q3 growth. Artegraft sales increased 18%.
EMEA sales increased by 18%, Americas 9%, and APAC 5%. 12% organic growth was
comprised of 7% price and 5% units. Gross margin of 71.7% was up 90 bps (vs.
adjusted) due to higher ASPs and operational efficiencies. Operating expenses
increased 18% (vs. adjusted) due to Q3 2025 belt-tightening. Headcount of 678
increased 7% versus 9/30/2025 while rep count increased 13% to 171. In October,
the company acquired certain vascular assets from B. Braun for $19.2mm. These
polyester and silver-coated grafts, valve cutters and vein strippers recorded
sales of $9.4mm in 2025, all outside of North America. Sales will transition
into LeMaitre’s channel over the next 18-24months as B. Braun’s customer
contracts conclude or transfer to LeMaitre. During this transition, LeMaitre
will receive a portion of the profits on B. Braun-originated sales. Chairman/CEO
George LeMaitre said, “We expect 2026 to be another year of healthy sales (+11%)
and EPS growth (+18%). Biologics continue to drive sales due to Artegraft’s
international launch and the continued growth of RestoreFlow Allografts. The
acquired B. Braun products will strengthen our core vascular portfolio while
leveraging our expanding 31-countrysales force.” Business Outlook
                                                                                
                      Q4 2026 Guidance              Full Year 2026 Guidance     
                      $69.9mm - $71.9mm             $274.8mm - $276.8mm         
  Sales               (Mid $70.9mm, +10%, +11%      (Mid $275.8mm, +11%, +11%   
                      org.)                         org.)                       
  Gross Margin        72.1%                         72.1%                       
                      $18.8mm - $20.2mm             $74.6mm - $76.1mm           
  Op. Income          (Mid $19.5mm, +4%)            (Mid $75.4mm, +11%, +17%    
                                                    adj.)                       
  Op. Margin (Mid)    27%                           27%                         
                      $0.70 - $0.75                 $2.77 - $2.82               
  EPS                 (Mid $0.73, +7%)              (Mid $2.80, +11%, +18%      
                                                    adj.)                       
                                                                                
                                                                                
     The top- and bottom-line impacts of the newly acquired B. Braun            
  *  products are reflected in this Business Outlook. LeMaitre anticipates      
     recording ~$150,000 of Q4 2026 B. Braun product sales and break-even       
     operating income impact.                                                   
                                                                                
                                                                                
      2025 results include a Q3 non-recurring benefit from the Employee         
  **  Retention Tax Credit. Non-GAAP adjusted figures exclude this benefit. A   
      reconciliation of GAAP to non-GAAP measures is included.                  
                                                                                
Quarterly Dividend On October 27, 2026, the Company’s Board of Directors
approved a quarterly dividend of $0.25/share of common stock. The dividend will
be paid on December 3, 2026, to stockholders of record on November 19, 2026.
Share Repurchase Program On February 19, 2026, the Company’s Board of Directors
authorized the repurchase of up to $100.0mm of the Company’s common stock. The
repurchase program may be suspended or discontinued at any time and will
conclude on February 18, 2027, unless extended by the Board.

Conference Call Reminder

Management will conduct a conference call at 5:00pm ET today. The conference
call will be broadcast live over the Internet. Individuals interested in
listening to the webcast can log on to the Company’s website at . Access to the
live call is available by registering online . All registrants will receive
dial-in information and a PIN allowing them to access the live call. The audio
webcast can also be accessed live or via replay through a webcast at . For
individuals unable to
join the live conference call, a replay will be available on the Company’s
website.

A reconciliation of GAAP to
non-GAAP results is included in the tables attached to this release.

About LeMaitre

LeMaitre is a provider of devices, implants, and services for the treatment of
peripheral vascular disease, a condition that affects more than
200 million people worldwide. The Company develops, manufactures, and markets
disposable and implantable vascular devices to address the needs of its core
customer, the vascular surgeon.

LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release
may include other trademarks and trade names of the Company.

For more information about the Company, please visit .

Use of Non-GAAPFinancial Measures

LeMaitre management believes that in order to better understand the Company’s
short- and long-term financial trends, investors may wish to consider
certain non-GAAP financial measures as a supplement to financial performance
measures prepared in accordance with GAAP. Non-GAAP financial measures are not
based on a
comprehensive set of accounting rules or principles and do not have standardized
meanings. These non-GAAP measures result from facts and circumstances that may
vary in frequency and/or impact on continuing
operations. Non-GAAP measures should be considered in addition to, and not as a
substitute for, GAAP financial performance measures. In addition to the
description provided below, reconciliation of GAAP to non-GAAP results is
provided in the financial statement tables included in this press release.

In this press release,
the Company has reported non-GAAP sales growth percentages after adjusting for
the impact of foreign currency exchange, business development transactions,
and/or other events. The Company refers to the
calculation of non-GAAP sales growth percentages as “organic” or “adjusted.” The
Company analyzes non-GAAP sales on a constant currency basis,
net of acquisitions and other non-recurring events. Because changes in foreign
currency exchange rates have a non-operating impact on net sales, and
acquisitions,
divestitures, product discontinuations, factory closures, and other strategic
transactions are episodic in nature and are highly variable to the reported
sales results, the Company believes that evaluating growth in sales on a
constant currency
basis net of such transactions provides an additional and meaningful assessment
of sales to management. Additionally, the Company has provided percentages for
Q3 2026 operating income, gross margin, operating expense and EPS, as well as
operating
income and EPS guidance, adjusted to exclude the effects of the employee
retention tax credit received in 2025. Management believes that viewing growth
in these measures excluding those effects provides an alternative and meaningful
view of the
Company’s profitability.

Investors are encouraged to review the reconciliation of these non-GAAP
financial
measures to their most directly comparable GAAP financial measures set forth in
the tables captioned “Reconciliation of GAAP to Non-GAAP Financial Measures”
below.

Forward-Looking Statements

The Company’s current
financial results, as discussed in this release, are preliminary and unaudited,
and subject to adjustment. This press release contains forward-looking
statements within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995.
Statements in this press release regarding the Company’s business that are not
historical facts may be “forward-looking statements” that involve risks and
uncertainties. Forward-looking statements are based on management’s
current, preliminary expectations and are subject to risks and uncertainties
that could cause actual results to differ from the results expected, including,
but not limited to, our ability to maintain historic levels of profit growth;
our ability to
increase the selling prices of our products; the status of our regulatory
approvals, compliance with regulatory requirements, and the potential for
adverse regulatory findings or enforcement actions arising from inspections,
audits, or other
regulatory reviews, affecting our ability to market and sell our products
domestically and internationally; our ability to source, acquire, and integrate
acquisitions; our dependence on sole- or limited-source suppliers; competition
from other
medical device companies and alternative medical technologies; our ability to
engage sales call points other than vascular surgeons; disruptions to our
information technology systems or breaches of our information security systems;
our
implementation of our new enterprise resource planning system; our ability to
procure, process, and preserve human tissue and comply with relevant regulatory
requirements; the impact of a disruption in our manufacturing facilities; our
ability to
navigate the risks inherent in operating internationally; our ability to
transition to direct sales models in certain international territories; the
occurrence of

litigation relating to product liability, employment matters, intellectual
property, contract disputes, and other matters; the occurrence of product
defects or recalls; our ability to service and
repurchase our debt; the dilutive effect of a conversion of our debt; our
ability to navigate executive officer transitions and retain key personnel; our
ability to protect our intellectual property; volatility in the price of our
common stock; and
other risks and uncertainties included under the heading “Risk Factors” in our
most recent Annual Report on Form 10-K, as updated by our subsequent filings
with the SEC, which are all
available on the Company’s investor relations website at http://www.lemaitre.com
and on the SEC’s website at http://www.sec.gov. Undue reliance should not be
placed on forward-looking statements, which speak only
as of the date they are made. The Company undertakes no obligation to update
publicly any forward-looking statements to reflect new information, events, or
circumstances after the date they were made, or to reflect the occurrence of
unanticipated
events.

Contact:

[email protected]

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in thousands)
                                                                                
                    September 30,                  December 31,                 
                    2026                           2025                         
 ────────────────────────────────────────────────────────────────────────────── 
                    -unaudited                                                  
  Assets                                                                        
  Current                                                                       
  assets:                                                                       
  Cash and cash     $                 27,493       $                 28,244     
  equivalents                                                                   
  Short-term                                                                    
  marketable                         362,228                        330,876     
  securities                                                                    
  Accounts                                                                      
  receivable,                         35,876                         33,610     
  net                                                                           
  Inventory and                                                                 
  other deferred                      71,272                         70,422     
  costs                                                                         
  Prepaid                                                                       
  expenses and                         8,642                          5,080     
  other current                                                                 
  assets                                                                        
  Total current                      505,511                        468,232     
  assets                                                                        
  Property and                        30,465                         26,997     
  equipment, net                                                                
  Right-of-use                        18,503                         15,762     
  leased assets                                                                 
  Goodwill                            65,945                         65,945     
  Other                                                                         
  intangibles,                        29,295                         33,089     
  net                                                                           
  Deferred tax                           746                            759     
  assets                                                                        
  Other assets                         5,567                          4,906     
  Total assets      $                656,032       $                615,690     
  Liabilities                                                                   
  and                                                                           
  stockholders’                                                                 
  equity                                                                        
  Current                                                                       
  liabilities:                                                                  
  Accounts          $                  4,159       $                  3,646     
  payable                                                                       
  Accrued                             26,686                         29,411     
  expenses                                                                      
  Acquisition-r…                         583                            322     
  obligations                                                                   
  Lease                                                                         
  liabilities -                        3,192                          2,944     
  short-term                                                                    
  Total current                       34,620                         36,323     
  liabilities                                                                   
  Convertible                                                                   
  senior notes,                      169,317                        168,645     
  net                                                                           
  Lease                                                                         
  liabilities -                       16,342                         14,003     
  long-term                                                                     
  Deferred tax                         2,167                          1,735     
  liabilities                                                                   
  Other                                                                         
  long-term                            1,455                          1,468     
  liabilities                                                                   
  Total                              223,901                        222,174     
  liabilities                                                                   
  Stockholders’                                                                 
  equity                                                                        
  Common stock                           245                            244     
  Additional                                                                    
  paid-in                            238,938                        228,407     
  capital                                                                       
  Retained                           215,324                        184,715     
  earnings                                                                      
  Accumulated                                                                   
  other                               (4,460  )                      (2,411  )  
  comprehensive                                                                 
  loss                                                                          
  Treasury stock                     (17,916  )                     (17,439  )  
  Total                                                                         
  stockholders’                      432,131                        393,516     
  equity                                                                        
  Total                                                                         
  liabilities                                                                   
  and               $                656,032       $                615,690     
  stockholders’                                                                 
  equity                                                                        
                                                                                
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) CONDENSED CONSOLIDATED STATEMENT OF
OPERATIONS (amounts in thousands, except per share amounts) (unaudited)
                                                                                
           For                                 For                              
           the                                 the                              
           three   Sept…          Septe…       nine   Septe…          Sept…     
           months    30,             30,       mont…     30,            30,     
           ended    2026            2025       ended    2026           2025     
 ────────────────────────────────────────────────────────────────────────────── 
  Net      $       67,9…       $  61,046       $      204,9…       $  185,…     
  sales                                                                         
  Cost                                                                          
  of               19,2…          15,091              57,038          52,8…     
  sales                                                                         
  Gross            48,7…          45,955              147,8…          132,…     
  prof…                                                                         
  Oper…                                                                         
  expe…                                                                         
  Sales                                                                         
  and              14,5…          11,923              43,429          41,0…     
  mark…                                                                         
  Gene…                                                                         
  and              12,0…          10,750              35,239          31,6…     
  admi…                                                                         
  Rese…                                                                         
  and              4,421           2,970              13,328          10,6…     
  deve…                                                                         
  Total                                                                         
  oper…            31,0…          25,643              91,996          83,2…     
  expe…                                                                         
  Inco…                                                                         
  from             17,6…          20,312              55,869          49,0…     
  oper…                                                                         
  Other                                                                         
  inco…                                                                         
  (exp…                                                                         
  Inve…            3,365           3,864              10,075          9,747     
  inco…                                                                         
  Inte…            (1,3…  )       (1,297  )           (3,906  )       (3,8…  )  
  expe…                                                                         
  Other                                                                         
  inco…              (82  )         (306  )             (503  )         (57  )  
  (los…                                                                         
  net                                                                           
  Inco…                                                                         
  befo…            19,6…          22,573              61,535          54,8…     
  inco…                                                                         
  taxes                                                                         
  Prov…                                                                         
  for              4,650           5,211              13,782          12,7…     
  inco…                                                                         
  taxes                                                                         
  Net      $       15,0…       $  17,362       $      47,753       $  42,1…     
  inco…                                                                         
  Earn…                                                                         
  per                                                                           
  share                                                                         
  of                                                                            
  comm…                                                                         
  stock                                                                         
  Basic    $        0.66       $    0.77       $        2.09       $   1.86     
  Dilu…    $        0.65       $    0.75       $        2.07       $   1.84     
  Weig…                                                                         
  -                                                                             
  aver…                                                                         
  shar…                                                                         
  outs…                                                                         
  Basic            22,8…          22,660              22,844          22,6…     
  Dilu…            23,0…          24,392              23,064          22,9…     
  Cash                                                                          
  divi…                                                                         
  decl…    $        0.25       $    0.20       $        0.75       $   0.60     
  per                                                                           
  comm…                                                                         
  share                                                                         
                                                                                
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) CONDENSED CONSOLIDATED STATEMENT OF CASH
FLOWS (amounts in thousands) (unaudited)
                                                                                
                    For the nine     September 30,            September 30,     
                    months ended              2026                     2025     
 ────────────────────────────────────────────────────────────────────────────── 
  Operating                                                                     
  activities                                                                    
  Net income        $                       47,753       $           42,152     
  Adjustments to                                                                
  reconcile net                                                                 
  income to                                                                     
  net cash                                                                      
  provided by                                                                   
  operating                                                                     
  activities                                                                    
  Depreciation                                                                  
  and                                        8,170                    7,813     
  amortization                                                                  
  Stock-based                                6,056                    5,730     
  compensation                                                                  
  Amortization                                                                  
  of issuance                                                                   
  costs on                                     672                      653     
  convertible                                                                   
  notes                                                                         
  Non-cash                                                                      
  investment                                  (253  )                     —     
  income                                                                        
  Provision for                                                                 
  inventory                                  2,548                    1,893     
  write-downs                                                                   
  Provision for                                675                      455     
  credit losses                                                                 
  Foreign                                                                       
  currency                                                                      
  transaction                                  316                      (79  )  
  effect on                                                                     
  income                                                                        
  Changes in                                                                    
  operating                                                                     
  assets and                                                                    
  liabilities:                                                                  
  Accounts                                  (3,347  )                (1,403  )  
  receivables                                                                   
  Inventory and                                                                 
  other deferred                            (3,584  )                (6,805  )  
  costs                                                                         
  Prepaid                                                                       
  expenses and                              (4,244  )                 1,639     
  other assets                                                                  
  Accounts                                                                      
  payable and                                 (636  )                 5,327     
  other                                                                         
  liabilities                                                                   
  Accrued                                   (1,078  )                   719     
  interest                                                                      
  Net cash                                                                      
  provided by                               53,048                   58,094     
  operating                                                                     
  activities                                                                    
  Investing                                                                     
  activities                                                                    
  Purchases of                                                                  
  short-term                              (390,987  )               (43,015  )  
  marketable                                                                    
  securities                                                                    
  Purchases of                                                                  
  property and                              (7,429  )                (5,006  )  
  equipment                                                                     
  Payments                                                                      
  related to                                                                    
  acquisitions,                               (194  )                   (95  )  
  net of                                                                        
  cash acquired                                                                 
  Proceeds from                                                                 
  short-term                               358,201                        —     
  marketable                                                                    
  securities                                                                    
  Net cash used                                                                 
  in investing                             (40,409  )               (48,116  )  
  activities                                                                    
  Financing                                                                     
  activities                                                                    
  Proceeds from                                                                 
  stock option                               4,473                    4,657     
  exercises                                                                     
  Deferred                                                                      
  payments for                                 (95  )                (1,433  )  
  acquisitions                                                                  
  Payment of                                                                    
  withholding                                                                   
  taxes in                                                                      
  connection                                  (477  )                  (605  )  
  with net                                                                      
  settlement of                                                                 
  equity                                                                        
  awards                                                                        
  Common stock                                                                  
  cash dividend                            (17,144  )               (13,572  )  
  paid                                                                          
  Net cash used                                                                 
  in financing                             (13,243  )               (10,953  )  
  activities                                                                    
  Effect of                                                                     
  exchange rate                                                                 
  changes on                                  (147  )                   859     
  cash                                                                          
  and cash                                                                      
  equivalents                                                                   
  Net (decrease)                                                                
  increase in                                 (751  )                  (116  )  
  cash and cash                                                                 
  equivalents                                                                   
  Cash and cash                                                                 
  equivalents at                            28,244                   25,610     
  beginning                                                                     
  of period                                                                     
  Cash and cash                                                                 
  equivalents at    $                       27,493       $           25,494     
  end of                                                                        
  period                                                                        
                                                                                
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) SELECTED NET SALES INFORMATION (amounts
in thousands) (unaudited)
                                                                                
      …                                     …                                   
      …                                     …                                   
      …  …                  …               …  …                  …             
      …  …                  …               …  …                  …             
      …  …                  …               …  …                  …             
 ────────────────────────────────────────────────────────────────────────────── 
      $       %          $       %          $       %          $       %        
                                                                                
      $  …       …  %    $  …       …  %    $  …       …  %    $  …       …  %  
         …       …  %       …       …  %       …       …  %       …       …  %  
         …       6  %       …       7  %       …       7  %       …       7  %  
      $  …       …  %    $  …       …  %    $  …       …  %    $  …       …  %  
                                                                                
LEMAITRE VASCULAR, INC (NASDAQ: LMAT) RECONCILIATION OF GAAP TO NON-
GAAPFINANCIAL MEASURES (amounts in thousands) (unaudited)
                                                                                
           For                                 For                              
           the                                 the                              
           three   Sept…          Septe…       nine   Septe…          Sept…     
           months    30,             30,       mont…     30,            30,     
           ended    2026            2025       ended    2026           2025     
 ────────────────────────────────────────────────────────────────────────────── 
  Reco…                                                                         
  betw…                                                                         
  GAAP                                                                          
  Net                                                                           
  Inco…                                                                         
  and                                                                           
  Non-…                                                                         
  Adju…                                                                         
  EBIT…                                                                         
  Net                                                                           
  inco…    $       15,0…       $  17,362       $      47,753       $  42,1…     
  as                                                                            
  repo…                                                                         
  Empl…                                                                         
  rete…                                                                         
  tax                  —          (3,380  )                —          (3,3…  )  
  cred…                                                                         
  net                                                                           
  Inte…                                                                         
  (inc…            (2,0…  )       (2,567  )           (6,169  )       (5,8…  )  
  expe…                                                                         
  net                                                                           
  Amor…                                                                         
  and              2,885           2,612               8,170          7,812     
  depr…                                                                         
  expe…                                                                         
  Prov…                                                                         
  for              4,650           5,211              13,782          12,7…     
  inco…                                                                         
  taxes                                                                         
  Adju…    $       20,4…       $  19,238       $      63,536       $  53,4…     
  EBIT…                                                                         
  Adju…                                                                         
  EBIT…                7  %                                              19  %  
  perc…                                                                         
  incr…                                                                         
                                                                                
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) RECONCILIATION OF GAAP TO NON-
GAAPFINANCIAL MEASURES (amounts in thousands) (unaudited)
                                                                                
  Reconciliation between GAAP and                                               
  Non-GAAP sales                                                                
  growth:                                                                       
  For the three months ended                                                    
  September 30, 2026                                                            
 ────────────────────────────────────────────────────────────────────────────── 
  Net sales as reported                 $  67,970                               
  Impact of currency exchange rate            439                               
  fluctuations                                                                  
  Adjusted net sales                                    $  68,409               
  For the three months ended                                                    
  September 30,                                                                 
  2025                                                                          
  Net sales as reported                 $  61,046                               
  Adjusted net sales                                    $  61,046               
  Adjusted net sales increase for                                               
  the                                                   $   7,363        12  %  
  three months ended September 30,                                              
  2026                                                                          
  Reconciliation between GAAP and                                               
  Non-GAAP gross margin                                                         
  growth:                                                                       
  For the three months ended                                                    
  September 30,                                                                 
  2026                                                                          
  Gross margin as reported                   71.7  %                            
  Adjusted gross margin                                      71.7  %            
  For the three months ended                                                    
  September 30,                                                                 
  2025                                                                          
  Gross margin as reported                   75.3  %                            
  Employee Retention Tax Credit              -4.5  %                            
  impact                                                                        
  Adjusted gross margin                                      70.8  %            
  Adjusted gross margin increase for                                            
  the                                                                   0.9  %  
  three months ended September 30,                                              
  2026                                                                          
  Reconciliation between GAAP and                                               
  Non-GAAP operating expense                                                    
  growth:                                                                       
  For the three months ended                                                    
  September 30,                                                                 
  2026                                                                          
  Operating expense as reported         $  31,010                               
  Adjusted operating expense                            $  31,010               
  For the three months ended                                                    
  September 30,                                                                 
  2025                                                                          
  Operating expense as reported         $  25,643                               
  Employee Retention Tax Credit               667                               
  impact                                                                        
  Adjusted operating expense                            $  26,310               
  Adjusted operating expense                                                    
  increase for                                                                  
  the three months ended September                      $   4,700        18  %  
  30,                                                                           
  2026                                                                          
  Reconciliation between GAAP and                                               
  Non-GAAP operating income                                                     
  growth:                                                                       
  For the three months ended                                                    
  September 30,                                                                 
  2026                                                                          
  Operating income as reported          $  17,695                               
  Adjusted operating income                             $  17,695               
  For the three months ended                                                    
  September 30,                                                                 
  2025                                                                          
  Operating income as reported          $  20,312                               
  Employee Retention Tax Credit            (3,380  )                            
  impact                                                                        
  Adjusted operating income                             $  16,932               
  Adjusted operating income increase                                            
  for                                                                           
  the three months ended September                      $     763         5  %  
  30,                                                                           
  2026                                                                          
  Reconciliation between GAAP and                                               
  Non-GAAP earnings per                                                         
  share growth:                                                                 
  For the three months ended                                                    
  September 30,                                                                 
  2026                                                                          
  Earnings per share as reported        $    0.65                               
  Adjusted earnings per share                           $    0.65               
  For the three months ended                                                    
  September 30,                                                                 
  2025                                                                          
  Earnings per share as reported        $    0.75                               
  Employee Retention Tax Credit             (0.13  )                            
  impact                                                                        
  Adjusted earnings per share                           $    0.62               
  Adjusted earnings per share                                                   
  increase for                                                                  
  the three months ended September                      $    0.03         5  %  
  30,                                                                           
  2026                                                                          
                                                                                
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) RECONCILIATION OF GAAP TO NON-
GAAPFINANCIAL MEASURES (amounts in thousands) (unaudited)
                                                                                
  Reconciliation between GAAP and                                               
  Non-GAAP projected sales                                                      
  growth:                                                                       
  For the three months ending December                                          
  31, 2026                                                                      
 ────────────────────────────────────────────────────────────────────────────── 
  Net sales per guidance (midpoint)       $   70,900                            
  Impact of currency exchange rate               507                            
  fluctuations                                                                  
  Adjusted projected net sales                             $   71,407           
  For the three months ended December                                           
  31,                                                                           
  2025                                                                          
  Net sales as reported                   $   64,453                            
  Adjusted net sales                                       $   64,453           
  Adjusted projected net sales                                                  
  increase                                                                      
  for the three months ending December                     $    6,954    11  %  
  31,                                                                           
  2026                                                                          
  Reconciliation between GAAP and                                               
  Non-GAAP projected sales                                                      
  growth:                                                                       
  For the year ending December 31,                                              
  2026                                                                          
  Net sales per guidance (midpoint)       $  275,800                            
  Impact of currency exchange rate            (1,433  )                         
  fluctuations                                                                  
  Adjusted projected net sales                             $  274,367           
  For the year ended December 31, 2025                                          
  Net sales as reported                   $  249,602                            
  Net impact of divestitures excluding        (1,839  )                         
  currency                                                                      
  Adjusted net sales                                       $  247,763           
  Adjusted projected net sales                                                  
  increase                                                 $   26,604    11  %  
  for the year ending December 31,                                              
  2026                                                                          
  Reconciliation between GAAP and                                               
  Non-GAAP projected                                                            
  operating income growth:                                                      
  For the year ending December 31,                                              
  2026                                                                          
  Operating income per guidance           $   75,400                            
  (midpoint)                                                                    
  Projected operating income                               $   75,400           
  For the year ended December 31, 2025                                          
  Operating income as reported            $   67,912                            
  Impact of employee retention credit         (3,380  )                         
  Adjusted operating income                                $   64,532           
  Adjusted projected operating income                                           
  increase for the year ending                             $   10,868    17  %  
  December                                                                      
  31, 2026                                                                      
  Reconciliation between GAAP and                                               
  Non-GAAP earnings per                                                         
  share growth:                                                                 
  For the year ending December 31,                                              
  2026                                                                          
  Earnings per share per guidance         $     2.80                            
  (midpoint)                                                                    
  Projected earnings per share                             $     2.80           
  For the year ended December 31, 2025                                          
  Earnings per share as reported          $     2.52                            
  Impact of employee retention credit          (0.14  )                         
  Adjusted earnings per share                              $     2.38           
  Adjusted projected earnings per                                               
  share                                                                         
  increase for the year ending                             $     0.42    18  %  
  December                                                                      
  31, 2026                                                                      
                                                                                

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LMAT/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.